Your browser doesn't support javascript.
loading
One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient.
Choo, Hun Gu; Lee, Jin Hae; Oh, Hyun Sub; Kim, Soon Hyun; You, Yong Sung; Kwon, Oh Woong.
Afiliação
  • Choo HG; Department of Ophthalmology, Wonju College of Medicine - Yonsei University, Wonju, Republic of Korea.
  • Lee JH; Department of Ophthalmology, First St. Marys Eye Clinic, Seoul, Republic of Korea.
  • Oh HS; Department of Ophthalmology, Nune Eye Hospital, Noon Bldg 404, Seonreung-ro Gangnam-gu, 06198, Seoul, Republic of Korea.
  • Kim SH; Department of Ophthalmology, Nune Eye Hospital, Noon Bldg 404, Seonreung-ro Gangnam-gu, 06198, Seoul, Republic of Korea.
  • You YS; Department of Ophthalmology, Nune Eye Hospital, Noon Bldg 404, Seonreung-ro Gangnam-gu, 06198, Seoul, Republic of Korea.
  • Kwon OW; Department of Ophthalmology, Nune Eye Hospital, Noon Bldg 404, Seonreung-ro Gangnam-gu, 06198, Seoul, Republic of Korea. owkwon0301@yuhs.ac.
BMC Ophthalmol ; 21(1): 94, 2021 Feb 18.
Article em En | MEDLINE | ID: mdl-33602156
ABSTRACT

BACKGROUND:

Polypoidal choroidal vasculopathy (PCV) is a type of age-related macular degeneration that can cause permanent vision loss. The purpose of this paper was to report the one-year outcomes of fixed-dosing aflibercept therapy for the treatment of PCV.

METHODS:

This was a prospective, single-arm, interventional case series study of 25 PCV patients; 12 pre-treated and 13 treatment-naïve patients. The patients were treated and monitored for 12 months. Each patient was administered with an aflibercept (2.0 mg) injection every month for the first 3 months (the loading phase), and thereafter, once every 2 months. At every follow-up visit, best-corrected visual acuity (BCVA) test, fundus examination, and optical coherence tomography for measuring the central subfield macular thickness (CSMT) were performed. Fluorescein and indocyanine green angiography were conducted at baseline and at 4 and 12 months.

RESULTS:

After 12 months of aflibercept therapy, the mean BCVA of the patients significantly improved from 65.48 letters at baseline to 69.91 letters (p=0.001), and the CSMT significantly decreased from 406.92 um at baseline to 276.12 um (p< 0.001). Additionally, ten patients (40%) showed complete polyp regression. The treatment-naïve patients showed a statistically significant improvement in BCVA from 66.58 letters at baseline to 76.36 letters at 12 months, and a significant decrease in CSMT, from 462 to 243 um. In the pre-treated group, there was no change in BCVA (64.46 letters), and the decrease in CSMT from 356.08 to 303.69 um was not statistically significant.

CONCLUSIONS:

The fixed-dosing aflibercept regimen is effective for treating patients with PCV and is more effective in treatment-naïve patients than in pre-treated patients. TRIAL REGISTRATION Clinical Research Information Service (CRiS), Republic of Korea. Identifer KCT0005798, Registered Jan 20, 2021. Retrospectively registered, URL https//cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=18546.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Fatores de Crescimento do Endotélio Vascular / Tomografia de Coerência Óptica Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans País como assunto: Asia Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Fatores de Crescimento do Endotélio Vascular / Tomografia de Coerência Óptica Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans País como assunto: Asia Idioma: En Ano de publicação: 2021 Tipo de documento: Article